The following studies are investigating the safety, immune responses, and effectiveness of different types of HIV vaccines. Because none of the vaccines being tested use whole, live, killed, or weakened HIV our participants cannot get HIV from these HIV vaccines. Instead, the vaccines use man-made imitations of pieces of the virus to try and trick the body’s immune system into creating a response to a threat that isn’t there.
HVTN 505 evaluates the safety and effectiveness of two different types of vaccines to examine whether this vaccine strategy prevents new HIV infections. The study also examines whether this vaccine strategy reduces the level of HIV virus in a person’s system if they do become infected. Click here to learn more about the recent NIH announcement regarding HVTN 505.
HVTN 077 evaluates the safety and preliminary immune response to two vaccines which use two disabled cold viruses carrying different HIV genes.
HVTN 083 evaluates the safety and immune response of giving two vaccines at different times, also known as a prime-boost vaccine strategy. The two vaccines being studied use two disabled cold viruses carrying different HIV genes to stimulate an immune response against HIV.
HVTN 205 investigates whether giving two different types of vaccines – a DNA vaccine and viral vector vaccine that uses a disabled small-pox like virus carrying HIV genes – is safe and creates strong and long-lasting immune responses.
HVTN 090 evaluates the safety and immune response of a viral vector vaccine that has been shown to prevent disease progression in monkeys infected with simian/human immunodeficiency virus (SHIV). The study will also determine the maximum dose that participants can safely receive.
HVTN 085 evaluates how a person’s immune system responds when different components of a disabled cold viral vector vaccine administered in both arms and both legs at one point in time.
HVTN 094 evaluates the safety, tolerability and immune system response of prime-boost regimens of two HIV vaccines: two injections of a DNA priming vaccine followed by either two or three boosting injections of a viral vector vaccine.
HVTN 092 evaluates the safety, tolerability and immune response of two different vaccines and several injection schedules to answer the question, “Does the amount of time between injections and the number of injections affect the way people’s immune systems respond to the vaccines?”
HVTN 105 evaluates the safety, tolerability and immune response of two different vaccines to answer the question, “Does the order in which the study vaccines are given affect how peoples immune systems respond to the vaccines?”
HVTN 106 evaluates the safety, tolerability and immune response of four different vaccines to answer the question, “Do different combinations of the study vaccines affect how peoples immune systems respond to the vaccines?”
HVTN 110 evaluates the safety, tolerability and immune response of two orally administered vaccines followed by an injected protein vaccine to answer the question, “Do different combinations of the oral vaccines have different effects on immune system responses to the vaccines?”